Indication: Ovarian Cancer

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rucaparib in combination with Nivolumab versus Placebo as Switch Maintenance Following Response to Front-Line Platinum-Based Chemotherapy in Patients with High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Patients with High-Grade Serous or Endometrioid

Sub-indication: Newly diagnosed, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer.

Line of Therapy: Maintance therapy following response to front line plantinum-based therapy.

Drug Study

Principal Investigator: Mary Gordinier, M.D.
Norton Cancer Institute

Sponsor: Clovis Oncology Inc.

Learn more at ClinicalTrials.gov

Email for more information: GYN-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.